LU90592I2
Fusion proteins with parts of immunoglobulins, their production and use
Abstract
The invention relates to genetically engineered soluble fusion proteins consisting of human proteins or parts thereof not belonging to the immunoglobulin family and various portions of the constant region of immunoglobulin molecules. The functional properties of both fusion components are surprisingly retained in the fusion protein.
Term
Term ended
Projected expiry passed 31 May 2020, 6.3 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
46 members in 18 offices
Priority claims3
| Document | Office | Kind | Date |
|---|---|---|---|
| 4020607 | Germany | A | |
| 4020607 | Germany | A | |
| DE19904020607 | – | – | – |
Members46
| Document | Office | Kind | |
|---|---|---|---|
| CA2045869A1 | Canada | A1 | |
| IE912256A1 | Ireland | A1 | |
| AU7935791A | Australia | A | |
| EP0464533A1 | European Patent Office (EPO) | A1 | |
| KR920000789A | Republic of Korea | A | |
| PT98113A | Portugal | A | |
| JPH05247094A | Japan | A | |
| AU655421B2 | Australia | B2 | |
| EP0835939A2 | European Patent Office (EPO) | A2 | |
| EP0835939A3 | European Patent Office (EPO) | A3 | |
| EP0464533B1 | European Patent Office (EPO) | B1 | |
| AT169030T | Austria | T | |
| ATE169030T1 | Austria | T1 | |
| DE59109032D1 | Germany | D1 | |
| ES2120949T3 | Spain | T3 | |
| GR3027567T3 | Greece | T3 | |
| PT98113B | Portugal | B | |
| DK0464533T3 | Denmark | T3 | |
| HK1010216A1 | Hong Kong, China | A1 | |
| HK1012015A1 | Hong Kong, China | A1 | |
| KR100249572B1 | Republic of Korea | B1 | |
| LU90592I2This record | Luxembourg | I2 | |
| NL300009I1 | Netherlands (Kingdom of the) | I1 | |
| NL300009I2 | Netherlands (Kingdom of the) | I2 | |
| KR100280069B1 | Republic of Korea | B1 | |
| KR100280070B1 | Republic of Korea | B1 | |
| UY25897A1 | Uruguay | A1 | |
| US2001053539A1 | United States of America | A1 | |
| JP2002201200A | Japan | A | |
| CY2151B1 | Cyprus | B1 | |
| US2003064480A1 | United States of America | A1 | |
| DE10075010I1 | Germany | I1 | |
| DE10075010I2 | Germany | I2 | |
| EP1586635A1 | European Patent Office (EPO) | A1 | |
| EP0835939B1 | European Patent Office (EPO) | B1 | |
| AT309376T | Austria | T | |
| ATE309376T1 | Austria | T1 | |
| DE59109269D1 | Germany | D1 | |
| EP0835939B8 | European Patent Office (EPO) | B8 | |
| DK0835939T3 | Denmark | T3 | |
| ES2251009T3 | Spain | T3 | |
| JP3768427B2 | Japan | B2 | |
| US7253264B1 | United States of America | B1 | |
| CA2045869C | Canada | C | |
| ES2120949T4 | Spain | T4 | |
| CY2000009I1 | Cyprus | I1 |
Numbers
- Publication, DOCDB
- 90592
- Publication, EPODOC
- LU90592I
- Application
- 90592
- Application, DOCDB
- 90592
- Application, EPODOC
- LU20000090592C
Titles2
- English
- Enbrel-etanercept
- French
- Enbrel-etanercept
Classification
- CPC, 18
- C07K16/00
- C07K16/18
- A61K38/00
- C07K14/47
- C07K14/505
- C07K14/7155
- C07K14/745
- C07K2319/00
- C07K2319/30
- C07K2319/32
- C07K2319/50
- C12N9/647
- C12N15/62
- A61P13/12
- A61P37/02
- A61P37/08
- A61P7/04
- A61P9/00
- IPC, 33
- C07K14 195
- A61K38 00
- A61K39 395
- A61P7 04
- A61P9 00
- A61P13 12
- A61P37 02
- A61P37 08
- C07K1 22
- C07K14 005
- C07K14 47
- C07K14 505
- C07K14 52
- C07K14 53
- C07K14 535
- C07K14 54
- C07K14 545
- C07K14 55
- C07K14 705
- C07K14 71
- C07K14 715
- C07K14 745
- C07K16 00
- C07K19 00
- C12N5 10
- C12N9 64
- C12N15 09
- C12N15 62
- C12P21 02
- C12R1 91
- G01N33 15
- G01N33 50
- G01N33 68